Literature DB >> 6593000

In vitro activity of HR 810, a new cephalosporin.

M A Bertram, D A Bruckner, L S Young.   

Abstract

The in vitro susceptibility of 409 clinical isolates to HR 810, a new cephalosporin, was evaluated and compared with their susceptibility to aztreonam, cefazolin, ceftazidime, imipenem, moxalactam, piperacillin, and gentamicin. On a weight basis, the activity of HR 810 against gram-negative bacilli was equivalent or superior to that of the other beta-lactam agents except imipenem.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6593000      PMCID： PMC284139          DOI： 10.1128/AAC.26.2.277

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Prolonged bleeding times and bleeding diathesis associated with moxalactam administration.

Authors:  M R Weitekamp; R C Aber
Journal:  JAMA       Date:  1983-01-07       Impact factor: 56.272

2.  Coagulopathy associated with the use of moxalactam.

Authors:  R L Pakter; T R Russell; C H Mielke; D West
Journal:  JAMA       Date:  1982-09-03       Impact factor: 56.272

3.  Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli.

Authors:  T O Kurtz; D J Winston; J A Hindler; L S Young; W L Hewitt; W J Martin
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

4.  Relation between beta-lactamase production and antimicrobial activity: comparison of the new compound HR 810 with cefotaxime.

Authors:  W Cullmann; W Opferkuch; M Stieglitz
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

5.  HR 810, a cephalosporin with low affinity for Enterobacter cloacae beta-lactamase.

Authors:  R M Tolxdorff-Neutzling; B Wiedemann
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

Review 6.  The new beta-lactamase-stable cephalosporins.

Authors:  H C Neu
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

7.  In vitro activity of HR 810, a new broad-spectrum cephalosporin.

Authors:  K Machka; I Braveny
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

8.  Randomized comparative study of moxalactam and cefazolin in the treatment of acute urinary tract infections in adults.

Authors:  A S Lea; A W Sudan; B A Wood; L O Gentry
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

9.  Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections.

Authors:  L C Preheim; R G Penn; C C Sanders; R V Goering; D K Giger
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

10.  Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy.

Authors:  R Platt; S L Ehrlich; J Afarian; T F O'Brien; J E Pennington; E H Kass
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191
View more
  13 in total

1.  In vitro activity of cefpirome (HR810) against Enterococcus species.

Authors:  P F Wheat; R C Spencer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-03       Impact factor: 3.267

2.  Microanalytical high-performance liquid chromatography assay for cefpirome (HR 810) in serum.

Authors:  C P Turley; G L Kearns; R F Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

3.  Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

4.  Disposition kinetics and urinary excretion of cefpirome after intravenous injection in buffalo calves.

Authors:  Neetu Rajput; Vinod K Dumka; Harpal S Sandhu
Journal:  J Vet Sci       Date:  2007-03       Impact factor: 1.672

Review 5.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

6.  In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents.

Authors:  A Tsuji; A Maniatis; M A Bertram; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

7.  Anti-pseudomonal activity of HR 810.

Authors:  M O Husson; D Izard; A Bryskier; H Leclerc
Journal:  Infection       Date:  1985 Mar-Apr       Impact factor: 3.553

8.  Comparative in vitro inhibitory and killing activity of cefpirome, ceftazidime, and cefotaxime against Pseudomonas aeruginosa, enterococci, Staphylococcus epidermidis, and methicillin-susceptible and -resistant and tolerant and nontolerant Staphylococcus aureus.

Authors:  E J Goldstein; D M Citron
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

9.  Beta-lactamase stability of cefpirome (HR 810), a new cephalosporin with a broad antimicrobial spectrum.

Authors:  S Kobayashi; S Arai; S Hayashi; K Fujimoto
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

10.  Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin.

Authors:  D Paradis; F Vallée; S Allard; C Bisson; N Daviau; C Drapeau; F Auger; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.